Back to Browse Journals » Infection and Drug Resistance » Volume 4

Meningococcal conjugate vaccines: optimizing global impact

Authors Terranella A, Cohn A, Clark T

Published Date September 2011 Volume 2011:4 Pages 161—169


Published 21 September 2011

Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2
1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

Abstract: Meningococcal conjugate vaccines have several advantages over polysaccharide vaccines, including the ability to induce greater antibody persistence, avidity, immunologic memory, and herd immunity. Since 1999, meningococcal conjugate vaccine programs have been established across the globe. Many of these vaccination programs have resulted in significant decline in meningococcal disease in several countries. Recent introduction of serogroup A conjugate vaccine in Africa offers the potential to eliminate meningococcal disease as a public health problem in Africa. However, the duration of immune response and the development of widespread herd immunity in the population remain important questions for meningococcal vaccine programs. Because of the unique epidemiology of meningococcal disease around the world, the optimal vaccination strategy for long-term disease prevention will vary by country.

Keywords: conjugate vaccine, meningitis, meningococcal vaccine, meningococcal disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Is Duane retraction syndrome part of the VACTERL association?

Akar S, Gokyigit B, Kavadarli I, Demirok A

Clinical Ophthalmology 2013, 7:581-585

Published Date: 20 March 2013

Update on the management of chronic rhinosinusitis

Cain RB, Lal D

Infection and Drug Resistance 2013, 6:1-14

Published Date: 23 January 2013

Overview of the epidemiology and the threat of Klebsiella pneumoniae carbapenemases (KPC) resistance

Chen LF, Anderson DJ, Paterson DL

Infection and Drug Resistance 2012, 5:133-141

Published Date: 24 September 2012

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S

ClinicoEconomics and Outcomes Research 2012, 4:237-243

Published Date: 3 September 2012

Prospective evaluation of simply modified MODS assay: an effective tool for TB diagnosis and detection of MDR-TB

Chaiyasirinroje B, Aung MN, Moolphate S, Kasetjaroen Y, Rienthong S, Rienthong D, Nampaisan O, Nedsuwan S, Sangchun W, Suriyon N, Mitarai S, Yamada N

Infection and Drug Resistance 2012, 5:79-86

Published Date: 7 May 2012

Recent developments in the epidemiology and management of tuberculosis – new solutions to old problems?

Thaiss WM, Thaiss CC, Thaiss CA

Infection and Drug Resistance 2012, 5:1-8

Published Date: 9 January 2012

Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles

Corem-Salkmon E, Ram Z, Daniels D, Perlstein B, Last D, Salomon S, Tamar G, Shneor R, Guez D, Margel S, Mardor Y

International Journal of Nanomedicine 2011, 6:1595-1602

Published Date: 3 August 2011

Multidrug and extensively drug-resistant tuberculosis from a general practice perspective

BM Yashodhara, Choo Beng Huat, Lakshmi Nagappa Naik, et al

Infection and Drug Resistance 2010, 3:115-122

Published Date: 22 October 2010